Page 11234..1020..»

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

By Dr. Matthew Watson

JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024.

Read the original post:
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

To Read More: Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
categoriaGlobal News Feed commentoComments Off on Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates | dataMarch 31st, 2025
Read All

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

By Dr. Matthew Watson

MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2024.

Here is the original post:
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

To Read More: HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
categoriaGlobal News Feed commentoComments Off on HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results | dataMarch 31st, 2025
Read All

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

By Dr. Matthew Watson

– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer –

Excerpt from:
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

To Read More: Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
categoriaGlobal News Feed commentoComments Off on Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | dataMarch 31st, 2025
Read All

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

By Dr. Matthew Watson

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

Originally posted here:
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors

To Read More: Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
categoriaGlobal News Feed commentoComments Off on Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors | dataMarch 31st, 2025
Read All

Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

By Dr. Matthew Watson

FARMINGDALE, N.Y., March 28, 2025 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced its intention to voluntarily delist its common stock from The New York Stock Exchange (“NYSE”) and to have its common stock quoted on the OTCQX Best Market (“OTCQX”).

Read more from the original source:
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

To Read More: Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
categoriaGlobal News Feed commentoComments Off on Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX | dataMarch 31st, 2025
Read All

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

By Dr. Matthew Watson

SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2024 and provided corporate updates.

Read the original post:
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

To Read More: Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
categoriaGlobal News Feed commentoComments Off on Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates | dataMarch 31st, 2025
Read All

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

By Dr. Matthew Watson

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates.

Follow this link:
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

To Read More: Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
categoriaGlobal News Feed commentoComments Off on Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results | dataMarch 31st, 2025
Read All

HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

By Dr. Matthew Watson

$171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024

Original post:
HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

To Read More: HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress
categoriaGlobal News Feed commentoComments Off on HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress | dataMarch 31st, 2025
Read All

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension…

By Dr. Matthew Watson

– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile –

Read more:
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension...

To Read More: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension…
categoriaGlobal News Feed commentoComments Off on Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension… | dataMarch 31st, 2025
Read All

Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery…

By Dr. Matthew Watson

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) in adults with type 2 diabetes and PAD, at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US1. These new data from the phase 3 trial were featured during a late-breaking clinical trial session at the ACC and simultaneously published today in The Lancet2.

Read the original here:
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery...

To Read More: Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery…
categoriaGlobal News Feed commentoComments Off on Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery… | dataMarch 31st, 2025
Read All

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

By Dr. Matthew Watson

CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place March 29 to April 2, 2025 in Chicago, Illinois, U.S.

See the article here:
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

To Read More: Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
categoriaGlobal News Feed commentoComments Off on Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress | dataMarch 31st, 2025
Read All

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

By Dr. Matthew Watson

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD)1. These new data from the phase 3b trial were featured during a late-breaking clinical trial session at the American College of Cardiology's (ACC) Annual Scientific Session and Expo in Chicago, US and simultaneously published today in New England Journal of Medicine2.

Originally posted here:
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

To Read More: Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
categoriaGlobal News Feed commentoComments Off on Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 | dataMarch 31st, 2025
Read All

First Three Children to Commence Treatment With Ryoncil®

By Dr. Matthew Watson

United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage United States Centers for Medicare and Medicaid Services (CMS) Mandates Ryoncil® Coverage

More:
First Three Children to Commence Treatment With Ryoncil®

To Read More: First Three Children to Commence Treatment With Ryoncil®
categoriaGlobal News Feed commentoComments Off on First Three Children to Commence Treatment With Ryoncil® | dataMarch 31st, 2025
Read All

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

By Dr. Matthew Watson

SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants.

Here is the original post:
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

To Read More: Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
categoriaGlobal News Feed commentoComments Off on Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study | dataMarch 31st, 2025
Read All

BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office

By Dr. Matthew Watson

BASEL, Switzerland, March 31, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR

Read the rest here:
BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office

To Read More: BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office
categoriaGlobal News Feed commentoComments Off on BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office | dataMarch 31st, 2025
Read All

Opthea Announces Decision to Discontinue Wet AMD Trials

By Dr. Matthew Watson

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52

View original post here:
Opthea Announces Decision to Discontinue Wet AMD Trials

To Read More: Opthea Announces Decision to Discontinue Wet AMD Trials
categoriaGlobal News Feed commentoComments Off on Opthea Announces Decision to Discontinue Wet AMD Trials | dataMarch 31st, 2025
Read All

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

By Dr. Matthew Watson

Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) to potentially expand the use of its chikungunya vaccine, IXCHIQ®, currently approved in adults1, to adolescents aged 12 to 17 years in the UK. This submission follows the recent positive opinion of the European Medicines Agency (EMA) on extension of IXCHIQ® label to adolescents in the European Union (EU)2.

Here is the original post:
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA

To Read More: Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
categoriaGlobal News Feed commentoComments Off on Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA | dataMarch 31st, 2025
Read All

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the…

By Dr. Matthew Watson

Basel, March 31, 2025 – Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. She will continue to report to Vas Narasimhan, M.D., CEO of Novartis and remain on the Executive Committee of Novartis (ECN). Klaus Moosmayer, currently Chief Ethics, Risk & Compliance Officer of Novartis, has decided to leave the company and will step down from the ECN to pursue his next chapter of leadership outside Novartis. The current Ethics Risk & Compliance (ERC) function will move under the leadership of Karen Hale. “Klaus has been integral to building trust with society by solving our legacy compliance topics and putting an ethics, risk and compliance system in place, which is regarded highly internally and externally. The impact he has had on our company, our people and our reputation will be long-lasting,” said Vas Narasimhan, CEO of Novartis. “I want to thank Klaus for his extraordinary leadership since he joined the company and ECN and wish him the very best as he pursues his next chapter. I have confidence that Karen will continue the strong commitment and rigor we have around ethics, risk management and compliance at Novartis.” Karen joined Novartis as Chief Legal Officer in May 2021, bringing almost 30 years of experience in resolving legal and compliance issues in the global pharmaceutical industry. Prior to joining Novartis, she held a succession of senior roles at AbbVie including vice president, deputy general counsel and chief ethics and compliance officer.“I am looking forward to leveraging the strengths of Legal and ERC to best align on risk management across the enterprise and to leading our efforts in ensuring our commitment to ethics, risk management, compliance and integrity remain unwavering,” said Karen Hale.Reflecting on his journey in ERC, Klaus Moosmayer shared, “after joining Novartis in 2018, I leave the company with a strong sense of pride on what we have accomplished together in strengthening our reputation and building a holistic integrated assurance system for Novartis.”DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Continued here:
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the...

To Read More: Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the…
categoriaGlobal News Feed commentoComments Off on Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the… | dataMarch 31st, 2025
Read All

AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances

By Dr. Matthew Watson

MILAN, March 31, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), announces the publication of their preclinical research in Stargardt’s disease in Science Advances, a prestigious peer-reviewed journal. This breakthrough study underscores the companies' joint commitment to advancing gene therapy and expanding the frontiers of scientific discovery.

Read the original post:
AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances

To Read More: AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances
categoriaGlobal News Feed commentoComments Off on AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances | dataMarch 31st, 2025
Read All

NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

By Dr. Matthew Watson

Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST

More here:
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025

To Read More: NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
categoriaGlobal News Feed commentoComments Off on NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 | dataMarch 31st, 2025
Read All

Page 11234..1020..»


Copyright :: 2025